CHILDRENS HOSPITAL 1990-2010. Protocol Revision and Outcome Marc - - PowerPoint PPT Presentation

▶

Dec 19, 2023 313 likes •548 views

RHABDOMYOSARCOMA AT RED CROSS WAR MEMORIAL CHILDRENS HOSPITAL 1990-2010. Protocol Revision and Outcome Marc Hendricks 1 , Alan Davidson 1 , Ann van Eyssen 1 , Komala Pillay 2 , Alp Numanoglu 3 , Alastair Millar 3 , Farieda Desai 1 , Paddy

SLIDE 1

RHABDOMYOSARCOMA AT RED CROSS WAR MEMORIAL CHILDREN’S HOSPITAL 1990-2010.

Protocol Revision and Outcome

Marc Hendricks1, Alan Davidson1, Ann van Eyssen1, Komala Pillay2, Alp Numanoglu3, Alastair Millar3, Farieda Desai1, Paddy Hartley1, Cyril Karabus1.

Haematology Oncology service, Red Cross War Memorial Children’s Hospital, Cape Town, South Africa.

SLIDE 2

Questions?

1. Has protocol revision impacted positively on survival?

2. Is the continued use of doxorubicin justified considering its potential for long

term cardiotoxicity given the evidence to suggest no survival benefit?

3. What is the best treatment for patients with irresectable stage 3 para-meningeal

tumours?

4. Did increased intensity make a difference for alveolar tumours?

SLIDE 3

Demographics

n = 115 biopsy proven rhabdomyosarcomas (RMS) on institutional registry 1990-2010. 40 exclusions:

3 absconded
5 missing or incomplete records
32 came for diagnosis or a component of their therapy but were primarily

treated at other centres (primarily PE or EL). n = 75 evaluable patients

SLIDE 4

n = 75 Age and gender 34 female (age 0-14.3 yrs; median 2.68 yrs) 41 male (age 0-14.25 yrs; median 5.39 yrs) Ethnicity 9 Caucasian, 38 Black, 28 Mixed ancestry 57 embryonal histology (ERMS) – 4 spindle cell variants (favourable) 1 anaplastic variant (unfavourable) 18 alveolar histology (ARMS) Stage 1 20 Stage 2 5 Stage 3 37 Stage 4 13

Stage 1 Group 1 Group 2 Group 3 20 7 2 11 10 1 Orbit 2 Head and neck (non-PM) 4 Orbit 3 Head and neck (non-PM) 10 6 Pelvis (non- bladder / non- prostate) including 1 Vaginal 4 Pelvis (non- bladder, non- prostate) including 3 Vaginal

SLIDE 5

SLIDE 6

Stage 1 Stage 2 Stage 3 Stage 4 Group 1 7

Group 2

2
Group 3

11 5 35

Group 4
13

3 Pulmonary 6 BM 4 Other

IRS Group and Stage

SLIDE 7

Site Number Orbit 5 Head and neck (non-PM)

Merks JH et al Ann Oncol 2014;25(1):231-6

15 Para-meningeal 17 Abdominal 5 Extremity 9 Vagina 6 Bladder 6 Pelvis (non-bladder, non-prostate) 11 No primary found 1

Site

SLIDE 8

Protocols over time…

Before 2003… [n=42]

SIOP MMT 89 Rx 6811 (Stage 1) - VA X 12/52 (Stage 2 ) - Weekly vincristine 12/52 and VAC/VDC 6 weekly X 24/52 (Stage 3 or 4) - As above but to 51/52 Rx 6911 VA X 54/52 Rx 6961 Adaptation of Rx 6811 similar to stage 3 and 4 plus IE/VDC Rx 8941 (Based on POG #8850 /CCSG #7881 (IE/VDC) Relapse protocol.

2003 – 2005… [n=5]

Rx 6031 (Stage 1 FH) VA X 21/52 Rx 6032 No patients. Rx 6033 (Stage 3 and 4 / All unfavourable histology) VAC/VDC X 51/52

After 2005… [n=28]

Rx 6051 (Group 1 /2 Orbit/Eyelid; Group 1 Para-testicular, FH only) VA 21/52 Rx 6052 (Group 1 /2 Head and neck (non-PM)/ Genitourinary / Extremity; Group 2 Para-testicular, FH only) VAC 30/52 Rx 6053 (All Group 3 excluding PM Stage 3 and Extremity Stage 3, FH only) VAC/VDC 51/52 Rx 6054 (Group 3 PM Stage 3, Extremity Stage 3; All Group 4; All UH [ARMS/UDS] IVA/VDC X 51/52

SLIDE 9

Toxicity

(Non-consecutive) Days of neutropaenia (0-99 days; median 6 days) (Non-consecutive) Days of antibiotics (0-95 days); median 7 days) No patients with cardiomyopathy.

Relapses (28)

14 on treatment 10 off treatment , <12 months 4 off treatment, > 12 months

Salvaged relapses

1 Stage 1 disease 1 Stage 2 disease

Results

SLIDE 10

39 long term survivors 29 died of disease 2 deaths from infection (low)

1 septic shock following final course of chemotherapy, not neutropaenic

[PM stage 4, group 4 ARMS]

1 septic shock and DIC following week 10 chemotherapy, not neutropaenic

[Extremity stage 3, group 3 ERMS]

1 lost

Outcomes

SLIDE 11

4 other/secondary malignancies

Metastatic adenocarcinoma of the rectum

(10 years off treatment)

[ERMS left proximal thigh stage 3, group 3 1993]

Rx 6811 (CPM TOTAL 2.8g [350mg/kg]) Abdominal relapse. Surgery + Rx 8941 + 12Gy XRT. (IFMTOTAL 30g [54g/m2])

Alkylator related + XRT?

Mesenchymal chondrosarcoma in left buttock and hemi-pelvis (12 years off treatment)

[ERMS of left psoas muscle stage 3, group 3 1995]

Rx 6811

XRT?

Osteogenic sarcoma of rib

(7.5 years off treatment)

[ARMS of right hemi-diaphragm stage 3, group 3 1995]

Rx 6811 (CPM TOTAL 2.8g [350mg/kg]) Chest wall relapse. Surgery + Rx 8941 (IFM TOTAL 15g [36g/m2])

Alkylator related + XRT?

Brain tumour (frontal)

(4.5 years off treatment)

[ERMS left labia stage 1, group 3 1996] Rx 6811

Cancer predisposition?

(5.3% vs. 3.2% Neglia et al. J Nat Can Inst 2001;93(8):618)

Outcomes

SLIDE 12

RMS at RCHH 1990-2010 Overall Survival by Group

Chi-square = 4.374965 df = 3 p = 0.22374

Complete Censored 50 100 150 200 250 Time in months 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Group 1 = 86% (n=7) Group 2 = 67% (n=4) Group 3 = 62% (n=51) Group 4 = 42% (n=13)

SLIDE 13

RMS at RCCH 1990-2010 Overall Survival by Stage

Chi-square = 6.426913 df = 3 p = 0.09261

Complete Censored 50 100 150 200 250 Time in months 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Stage 1 = 80% (n=20) Stage 2 = 80% (n=5) Stage 3 = 51% (n=30) Stage 4 = 42% (n=13)

SLIDE 14

RMS at RCCH 1990-2010 Overall Survival by Cohort Log-Rank Test p = 0.71939 Complete Censored 50 100 150 200 250 Time in months 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving 1990-2004 60% (n=46) 2005-2010 63% (n=29)

SLIDE 15

RMS at RCCH 1990-2010 Overall Survival by Histology Log-Rank Test p = 0.42222 Complete Censored 50 100 150 200 250 Time in months 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Embryonal 60% (n=52) Alveolar 55% (n=18)

SLIDE 16

RMS at RCCH 1990-2010 Overall Survival = 61% Complete Censored

50 100 150 200 250 Survival Time in months 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving

SLIDE 17

Conclusion

Proportionately larger numbers of tumours at adverse sites.
Deaths from infection were low (2/75).
Salvage rate post relapse was dismal (2/28).
Higher than expected rate of secondary / other malignancy (4/75) albeit that

this occurred in the earlier cohort of patients.

Trend to suggest that protocol revision / standardisation has positively impacted

survival over time:

pre-2003

OS 54.1%

2003-2005

OS 59.5%

2005-2010

OS 64.2%

SLIDE 18

Questions…?

Evidence…? (JPHO 2001 23(4):215 Raney B, Anderson JR, Barr FG et al) Adriamycin

IRSG I – III VAC-A + XRT no significant benefit over VAC + XRT (all p < 0.17) e.g. IRSG III all non-ARMS G II randomised VAC + XRT +/- Adria. No benefit from adriamycin even when results from IRSG II were added in.

Should we be changing…?

IRSG V (’97 -’01) 3 protocols according to risk of recurrence Low risk 3 yr FFS 88% VA or VAC + XRT Intermediate risk 55- 76% VAC +/- XRT +/- TopoT High risk <33% VAC + XRT +/- TopoT or IrinoT NO ANTHRCYCLINES! Given that the evidence suggests that there is no survival benefit using adriamycin, should we

mit anthracyclines considering we do not have any evidence to support that and considering

the absence of cardiomyopathy in our cohort suggesting there is no increased toxicity with its use?

SLIDE 19

Questions…?

ur group 3 stage 3 para-meningeal and extremity tumours, and
ur unfavourable histology (ARMS) patients with good risk anatomical disease (orbit)? –

cannot be answered by this cohort: only 1 patient treated on Rx6033 (ADF) and none

n Rx6054.

Protocols Total patients treated PM patients Survivors Rx 6033

(Stage 3 and 4 / All unfavourable histology)

VAC/VDC X 51/52

4 2 2 (100%)

Rx 6054

(Group 3 PM Stage 3, Extremity Stage 3; All Group 4; All UH [ARMS/UDS])

IVA/VDC X 51/52

12 7 3 (42%) Is VAC/VDC as good (or better than) IVA/VDC for:

SLIDE 20

Questions…?

Patients in historical cohort pre-2005 protocol provision were certainly doing no better. Perhaps we should retain IVA/VDC

for ARMS but revert Rx 6053 for para-meningeal stage 3 group 3 patients.

Protocols Total patients treated Alveolar patients Survivors All other protocols 15 15 4 (28.5%) ADF: Stage 1 3 (1 SM) Stage 4 1 Dead: Stage 1 2 Stage 2 2 Stage 3 2 Stage 4 3 (2 relapse, 1 infection) Lost 1 Rx 6054 (Group 3 PM Stage 3, Extremity Stage 3; All Group 4; All UH [ARMS/UDS]) IVA/VDC X 51/52 7 4 2 (50%) All stage 3 patients Still does not answer the question about patients who are ARMS but good risk by anatomical site.

Did IVA/VDC (Rx 6054) make a difference for alveolar tumours when compared to historical protocols?

SLIDE 21

Recommendations

1. Even in the absence of cardiomyopathy in this cohort, we still believe there is a place to limit the risk of anthracycline-related cardiotoxicity by further reducing the cumulative dose of doxorubicin to 300mg/m2 (currently 360mg/m2 on Rx6053 and Rx6054). 2. Treat all group 3, stage 3 (including para-meningeal and extremity) patients with VDC/VAC. 3. Treat all unfavourable histology (ARMS and UDS) and all metastatic (stage 4, group 4) patients with IVA/VDC.

SLIDE 22

Thanks

Felicity Douglas Research assistant /nurse for data collection Alan Davidson Clinical head of unit